18F-PSMA-1007 PET/CT与MRI以组织病理为参考标准在前列腺内肿瘤检测及高危前列腺癌T分期中的前瞻性比较
前瞻性纳入19例新诊断不利中危或高危前列腺癌患者,在机器人辅助腹腔镜前列腺切除术前行18F-PSMA-1007 PET/CT和全身MRI(WBMRI)联合DWI,以全mount前列腺切除标本为参考标准评估前列腺内肿瘤定位、精囊侵犯和前列腺外延伸的诊断准确性。PET/CT对前列腺内病灶总体检出率为84.6%和82.1%(两名独立阅片者),MRI为74.4%和46.2%;PET/CT检测前列腺外延伸的AUC为0.500-0.591,MRI为0.648-0.682;SUVmax与PSMA免疫组化表达乘以病灶直径呈弱相关(Spearman ρ=0.427,p=0.013)。
要点
- 18F-PSMA-1007 PET/CT对前列腺内癌灶定位显示高灵敏度,总体检出率84.6%和82.1%(两名阅片者)。
- 检测前列腺外延伸时PET/CT的AUC为0.500-0.591,似乎劣于WBMRI的0.648-0.682。
- SUVmax与PSMA免疫组化表达乘以病灶直径呈弱相关(ρ=0.427,p=0.013),提示PSMA摄取可能取决于表达和病灶大小。
核心结论
- 18F-PSMA-1007 PET/CT在前列腺内癌灶定位中显示高灵敏度,但在检测前列腺外延伸方面似乎劣于全身MRI。
- PSMA摄取似乎取决于PSMA表达和病灶大小两者。
- 这些发现突显了PET/CT和MRI在前列腺癌检测和肿瘤分期中的互补作用。
研究设计与样本
- 前瞻性比较研究,纳入新诊断不利中危或高危前列腺癌男性,在机器人辅助腹腔镜前列腺切除术前接受18F-PSMA-1007 PET/CT和全身MRI联合DWI。
- 以全mount前列腺切除标本为参考标准评估前列腺内肿瘤定位、精囊侵犯和前列腺外延伸的诊断准确性。
- 共纳入19例患者,组织病理学显示39个前列腺内病灶。
- 将SUVmax与使用QuPath软件量化的免疫组化PSMA染色强度进行比较。
- 临床试验注册号NCT03537391,注册日期2018年5月25日。
主要发现
- 前列腺内病灶总体检出率:PET/CT两名独立阅片者分别为84.6%和82.1%,MRI阅片者分别为74.4%和46.2%。
- 指数病灶检出率:PET/CT为94.7%,MRI为74.0-84.0%;非指数病灶检出率:PET/CT为70.0-75.0%,MRI为20.0-65.0%。
- 检测前列腺外延伸的AUC:PET/CT为0.500-0.591,MRI为0.648-0.682。
- 检测精囊侵犯的AUC:两种模态范围为0.629至0.700。
- SUVmax与PSMA免疫组化表达乘以病灶直径呈弱相关(Spearman ρ=0.427,p=0.013)。
关键数值与推荐
- 前列腺内病灶总体检出率:PET/CT 84.6%和82.1%(两名独立阅片者)vs MRI 74.4%和46.2%。
- 指数病灶检出率:PET/CT 94.7% vs MRI 74.0-84.0%。
- 非指数病灶检出率:PET/CT 70.0-75.0% vs MRI 20.0-65.0%。
- 前列腺外延伸检测AUC:PET/CT 0.500-0.591 vs MRI 0.648-0.682。
- 精囊侵犯检测AUC:两种模态范围0.629至0.700。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To prospectively compare the ability of 18F-PSMA-1007 PET/CT and whole-body MRI (WBMRI) with DWI to detect prostate cancer (PCa) lesions and assess their local stage. Additionally, to evaluate the correlation between PSMA uptake on PET/CT and PSMA expression as assessed by immunohistochemistry. METHODS: Men with newly diagnosed unfavourable intermediate or high-risk PCa underwent 18F-PSMA-1007 PET/CT and WBMRI with DWI before robot-assisted laparoscopic prostatectomy. Diagnostic accuracy for intraprostatic tumour localization, seminal vesicle invasion (SVI), and extraprostatic extension (EPE) was evaluated using whole-mount prostatectomy specimens as the reference standard. SUVmax was compared with immunohistochemical PSMA staining intensity quantified using QuPath software. RESULTS: 19 patients with 39 intraprostatic lesions in histopathology were included. The overall lesion detection rates for PET/CT were 84.6% and 82.1% for two independent readers, compared to 74.4% and 46.2% for MRI readers. The detection rates of index lesions were 94.7% for PET/CT and 74.0-84.0% for MRI, whereas those of non-index lesions were 70.0-75.0% for PET/CT and 20.0-65.0% for MRI. For detecting EPE, AUC values were 0.500-0.591 for PET/CT and 0.648-0.682 for MRI. For detecting SVI, AUC values ranged from 0.629 to 0.700 across both modalities. SUVmax showed a weak correlation with immunohistochemical expression of PSMA multiplied by lesion diameter (Spearman's ρ = 0.427, p = 0.013). Lesion diameters measured using 30% and 40% of SUVmax, as well as prostate SUVbackground x2, showed the closest agreement with histopathological measurements. CONCLUSION: 18F-PSMA-1007 PET/CT demonstrated high sensitivity in localizing intraprostatic carcinoma lesions but seemed inferior to WBMRI in detecting EPE. PSMA uptake appears to depend on both PSMA expression and lesion size. These findings highlight the complementary roles of PET/CT and MRI in the detection and tumor staging of PCa. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov ID: NCT03537391. Registered 25 May 2018.
引用
- Kivikallio A, Malaspina S, Saarinen I, et al. Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40159542. doi:10.1007/s00259-025-07208-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。